Edgewise Therapeutics, Inc. (EWTX)
NASDAQ:EWTX
Want to see EWTX full AI Analyst Report?
Top Page
Edgewise Therapeutics
(NASDAQ:EWTX)
Select Model
Select Model
Rating:66Neutral
Price Target:
$40.00
▲(16.18% Upside)
Action:Reiterated
Date:06/06/26
The score is driven mainly by strong balance sheet positioning (low leverage) and supportive technical trend, plus a major value-creating corporate event (large upfront cash from asset sale). These positives are tempered by the core financial risk of being pre-revenue with substantial ongoing losses and cash burn, and limited insight from traditional valuation metrics due to a negative P/E and no dividend.
Positive Factors
Strong Balance Sheet / Low Leverage
Extremely low debt relative to equity and sizable assets give the company durable funding flexibility to underwrite multi-year clinical programs. This reduces near-term insolvency risk, preserves strategic optionality for partnerships or organic development, and supports R&D continuity.
Negative Factors
Pre-Revenue Status
Being pre-revenue is a fundamental risk: without product sales the company depends on external funding or asset transactions to support costly development. This leaves long-term viability tied to clinical outcomes and financing access rather than operational cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Balance Sheet / Low Leverage
Extremely low debt relative to equity and sizable assets give the company durable funding flexibility to underwrite multi-year clinical programs. This reduces near-term insolvency risk, preserves strategic optionality for partnerships or organic development, and supports R&D continuity.
Read all positive factors
Edgewise Therapeutics (EWTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.01B
Dividend YieldN/A
Average Volume (3M)1.43M
Price to Earnings (P/E)―
Beta (1Y)2.05
Revenue GrowthN/A
EPS Growth-7.28%
CountryUS
Employees117
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.66
Shares Outstanding107,593,000
10 Day Avg. Volume1,529,564
30 Day Avg. Volume1,431,903
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)4.89
Price to Sales (P/S)0.00
P/FCF Ratio-17.76
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.18K
Enterprise Value/Ebitda-19.44
Forecast
1Y Price Target
$46.89Price Target Upside36.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.94
Revenue Forecast (FY)N/A
Edgewise Therapeutics Business Overview & Revenue Model
Company Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause o...
How the Company Makes Money
Edgewise Therapeutics primarily generates revenue, if any, through collaboration-related arrangements rather than product sales, because it is a clinical-stage company without widely commercialized products. Its potential revenue sources include: ...
Edgewise Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -590.00K | -2.27M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -187.57M | -165.53M | -156.54M | -112.63M | -71.12M | -42.94M |
| Net Income | -176.01M | -167.79M | -133.81M | -100.16M | -67.64M | -42.81M |
Balance Sheet | ||||||
| Total Assets | 518.52M | 552.60M | 486.82M | 340.04M | 367.10M | 285.23M |
| Cash, Cash Equivalents and Short-Term Investments | 499.56M | 530.11M | 470.17M | 318.39M | 351.95M | 280.79M |
| Total Debt | 3.79M | 3.99M | 4.74M | 5.41M | 4.41M | 0.00 |
| Total Liabilities | 25.32M | 30.35M | 27.60M | 21.20M | 20.39M | 10.85M |
| Stockholders Equity | 493.20M | 522.26M | 459.22M | 318.83M | 346.72M | 274.38M |
Cash Flow | ||||||
| Free Cash Flow | -148.71M | -143.82M | -110.34M | -97.69M | -58.18M | -34.17M |
| Operating Cash Flow | -148.49M | -143.82M | -109.03M | -91.95M | -52.63M | -33.51M |
| Investing Cash Flow | -74.25M | -32.79M | -184.66M | 102.89M | -70.58M | -242.23M |
| Financing Cash Flow | 206.04M | 196.09M | 249.25M | 53.17M | 129.64M | 186.38M |
Edgewise Therapeutics Technical Analysis
Positive
34.43
Price Trends
33.29
Positive
31.22
Positive
24.98
Positive
Market Momentum
1.07
Negative
59.40
Neutral
57.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EWTX, the sentiment is Positive. The current price of 34.43 is above the 20-day moving average (MA) of 34.36, above the 50-day MA of 33.29, and above the 200-day MA of 24.98, indicating a bullish trend. The MACD of 1.07 indicates Negative momentum. The RSI at 59.40 is Neutral, neither overbought nor oversold. The STOCH value of 57.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EWTX.
Edgewise Therapeutics Risk Analysis
Edgewise Therapeutics disclosed 86 risk factors in its most recent earnings report. Edgewise Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Edgewise Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $4.01B | -21.66 | -32.55% | ― | ― | -7.28% | |
52 Neutral | $2.19B | -10.41 | -67.40% | ― | ― | -5.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.83B | -4.47 | -60.70% | ― | 23382.78% | 7.01% | |
47 Neutral | $839.14M | -7.31 | -11.85% | ― | 47.10% | -35.51% | |
45 Neutral | $2.40B | -6.26 | -74.86% | ― | ― | -85.06% | |
45 Neutral | $1.72B | -2.46 | -866.46% | ― | ― | 39.46% |
* Healthcare Sector Average
EWTX
Edgewise Therapeutics
35.59
20.35
133.53%
VRDN
Viridian Therapeutics
15.78
1.10
7.49%
PHVS
Pharvaris
31.09
14.31
85.28%
VERA
Vera Therapeutics
32.29
9.59
42.25%
JANX
Janux Therapeutics Inc
13.36
-12.85
-49.03%
BHVN
Biohaven Ltd.
10.80
-6.23
-36.58%
Edgewise Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Edgewise Therapeutics Shareholders Back Board and Governance
Positive
Jun 5, 2026
Edgewise Therapeutics, Inc. held its Annual Meeting of stockholders on June 4, 2026, at which shareholders elected three Class II directors, Laura Brege, Badreddin Edris, Ph.D., and Jonathan Root, M.D., to serve until the 2029 annual meeting. Shar...
Business Operations and StrategyM&A Transactions
Edgewise Therapeutics Sells Sevasemten, Refocuses on Cardiology
Positive
Jun 1, 2026
On June 1, 2026, Edgewise Therapeutics announced a definitive agreement to sell sevasemten and its muscular dystrophy business to Servier for $1.55 billion in upfront cash and up to $1.1 billion in additional milestone payments, for potential tota...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.